The association of SPISE with cardiometabolic multimorbidity and stroke in middle-aged and older adults: a nationwide prospective cohort study.
A simple blood-test-derived insulin resistance score predicts heart disease and stroke risk, identifying candidates for earlier metabolic intervention.
This nationwide prospective study demonstrates that the SPISE index—a non-fasting insulin sensitivity estimator requiring only routine clinical measurements—independently predicts cardiometabolic multimorbidity and stroke risk in middle-aged and older adults. The findings support SPISE as a clinically accessible tool for identifying insulin-resistant individuals at elevated cardiometabolic risk who may benefit from earlier metabolic intervention.
What the study was
- Study design
- Nationwide prospective cohort study
- Population
- Middle-aged and older adults from a nationwide prospective study cohort
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Scientific reports
Why it surfaced
Nationwide prospective evidence for SPISE as a non-invasive, accessible insulin resistance biomarker for cardiometabolic and stroke risk stratification; SPISE requires no additional testing beyond a routine lipid panel and BMI.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.